Yi-Chen Lin, PhD | Scientist

Dr. Yi-Chen Lin is a Scientist at Pythia Biotech, specializing in translational oncology, tumor immunology, and oncology drug development. He received his Ph.D. in Life Sciences from the National Defense Medical Center and Academia Sinica, where his research focused on the molecular and cellular mechanisms underlying cancer progression and therapeutic response.



Prior to joining Pythia, Dr. Lin served as a Scientist at Anbogen Therapeutics, where he contributed to the development of novel oncology therapeutics across multiple cancer types, including pancreatic cancer, hepatocellular carcinoma, and urothelial carcinoma. His experience spans preclinical translational research, biomarker strategy development, PK/PD study design, and mechanism-of-action investigations.

At Pythia, Dr. Lin supports the development and application of the TME-Chip platform by integrating tumor biology, translational research, and biomarker science. His work focuses on generating human-relevant insights that help researchers better understand therapeutic response, identify predictive biomarkers, and accelerate oncology drug development.